Clinical Trial

A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 13, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to evaluate the safety and tolerability of HC010 monotherapy in patients with advanced solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-06; most recent amendment 2025-05-08.
Status change: Not Yet Recruiting → Recruiting 2024-04-08
Trial Details
NCT Number NCT06307925
Lead Sponsor HC Biopharma Inc.
Conditions Advanced Solid Tumor
Enrollment 122 participants
Start Date 2024-03-27
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-13